Company intelligence / Profile preview

Alnylam Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~2230
Development stage: Other

Overview

Alnylam has achieved multiple FDA and EMA approvals for first-in-class RNAi products (ONPATTRO/patisiran for hATTR amyloidosis, GIVLAARI/givosiran for acute hepatic porphyria, OXLUMO/lumasiran for primary hyperoxaluria type 1, AMVUTTRA/vutrisiran for ATTR amyloidosis polyneuropathy and cardiomyopathy, Qfitlia/fitusiran for hemophilia A and B), with positive late-stage results for zilebesiran (hypertension). These drugs demonstrate robust target protein knockdown, durable clinical benefit, and favorable safety profiles in their indications[2][6][12][16].

Therapeutic areas: HematologyCardiovascularRare Diseases
Modalities: Small interfering RNARNA therapy
Industry: Biotech

Partnerships

SanofiNovartisRegeneronRocheVir BiotechnologyPeptiDreamMonsanto (historic)Biogen (historic)

Beyond the preview

Go deeper on Alnylam Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alnylam Therapeutics.

Explore the full profile